Eli Lilly and Co. announced plans to spend $400 million for the expansion of its manufacturing capabilities at its Indianapolis campus. The expansion project will include added capacity for its diabetes medicines, improvements to its current facilities that produce insulin, and initial capital investments for future drugs and therapies to be developed.